Radiation oncology firm Accuray posted revenue increases and a lower net loss for its fourth quarter and fiscal 2018 (end-June 30).
For the quarter, Accuray had revenue of $113.8 million, up 2% from $112.1 million in the fourth quarter of 2017. The company posted a net loss of $900,000 for the quarter, compared with a net loss of $5.3 million in the same period last year.
For the fiscal year, Accuray had revenue of $404.9 million, up 6% from $383.4 million in fiscal 2017. The firm had a net loss of $23.9 million, down from 2017's net loss of $29.6 million.
For fiscal 2019, Accuray said it expects revenue ranging from $415 million to $425 million.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
